Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Aptorum Group Limited APM
$3.54
-$0.01 (-0.28%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
13107552.00000000
-
week52high
17.30
-
week52low
2.30
-
Revenue
0
-
P/E TTM
-4
-
Beta
-0.01806000
-
EPS
-62.28000000
-
Last Dividend
0.00000000
-
Next Earnings Date
28 апр 2023 г. в 12:00
Описание компании
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| China Renaissance | Buy | 02 апр 2019 г. | |
| HC Wainwright & Co. | Buy | 07 окт 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Why Is Aptorum (APM) Stock Down 16% Today?
InvestorPlace
08 мая 2023 г. в 08:43
Aptorum (NASDAQ: APM ) stock is falling on Monday after the company received a delisting notice from the Nasdaq Stock Market LLC. The reason given for the delisting notice is Aptorum failing to maintain proper equity to remain on The Nasdaq Global Market.
Aptorum Group shares double after merger plans, earnings delight investors
Proactive Investors
03 мая 2023 г. в 12:41
Aptorum Group saw its market capitalization double following a busy week where the biopharmaceutical firm released its latest results and announced a merger plan. Shares of the Nasdaq-listed company were up over 109% by midday Wednesday at US$5.85.
Why Is Aptorum (APM) Stock Up 166% Today?
InvestorPlace
03 мая 2023 г. в 07:55
Aptorum (NASDAQ: APM ) stock is climbing higher on Wednesday despite a lack of news from the clinical-stage biopharmaceutical company. However, trading of APM stock is taking off today with more than 1 million shares on the move.
7 Hot Small-Cap Stocks to Buy in September
InvestorPlace
02 сент 2022 г. в 06:45
In general, finding small-cap stocks to buy can be somewhat fraught. These are stocks with market capitalizations between roughly $300 million and $2 billion.
Aptorum Group Limited to Present at the H.C. Wainwright Annual Global Investment Conference, September 13-16, 2022
Business Wire
25 авг 2022 г. в 20:31
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that Mr. Darren Lui, CEO and Executive Director of Aptorum Group will present both in-person and virtually at the H.C. Wainwright Global Investment Conference, New York, being held on September 13-16, 2022. Aptorum Group management will be